CASE.EDU:    HOME | DIRECTORIES | SEARCH

 
Anthony J. Berdis
Assistant Professor
Department of Pharmacology

Phone: 216-368-4723
E-mail: anthony.berdis@case.edu

Office: School of Medicine, W343

Development and Implementation of Non-Natural Nucleosides and Nucleotides

DNA damaging agents represent an important component of modern chemotherapy. Unfortunately, the use of DNA damaging agents is often associated with debilitating side-effects as well as the potential for the development of therapy-related cancers that appear linked with chemotherapy. To combat these complications, our research program is developing a series of unique non-natural nucleoside analogs as adjunctive chemotherapeutic agents.

These analogs are designed to be selectively inserted opposite various pro-mutagenic DNA lesions that are caused by several chemotherapeutic DNA-damaging agents. Thus, they have the potential to behave as chemosensitizing and chemopreventive agents.

Evaluating the Contribution of pi-Electron Density During DNA Polymerization

Using principles of rational drug design, we have developed a library of non-natural indolyl nucleoside analogs. A subset of these non-natural ... Continue


Non-Natural Nucleosides as Chemotherapeutic Agents

Using principles of rational drug design, we have developed a library of non-natural indolyl nucleoside analogs. A subset of these non-natural nucleosides are unique as they ... Continue

Non-Natural Nucleosides as Chemopreventive Agents

There are over 1 million cases of skin cancer diagnosed yearly in the United States. Approximately 3% of those individuals diagnosed with skin cancer will die from metastatic melanoma. ... Continue

Back to Research Interests